SCK

Shengqi Capital (Hong Kong) Ltd. Portfolio

Invests via Shengqi Capital (Hong Kong) Ltd. | Managed by Lau Ka Chun
Invests via Shengqi Capital (Hong Kong) Ltd.
Managed by Lau Ka Chun
Automatically Tracked
Tracking: 0 Updated: 14 hours ago
Company Profile

Targets Greater China private equity opportunities across growth-stage technology, consumer and healthcare companies, deploying equity and structured capital through direct investments and co-investments for institutional and family-office clients. The firm leverages Hong Kong as a regional base to source cross-border deal flow between mainland China and global investors, emphasizing operational support, follow-on funding and exit preparation via strategic trade buyers or IPOs.

Targets Greater China private equity opportunities across growth-stage technology, consumer and healthcare companies, deploying equity and structured capital through direct investments and co-investments for institutional and family-office clients. The firm leverages Hong Kong as a regional base to source cross-border deal flow between mainland China and global investors, emphasizing operational support, follow-on funding and exit preparation via strategic trade buyers or IPOs.

Investment Philosophy & Strategy

Operates as a Greater China growth private equity allocator that prioritizes technology, consumer and healthcare leaders with clear paths to scalable revenue and cross-border expansion. Capital deployment blends direct equity, structured instruments and co‑investments to balance upside and downside protection, with staged follow‑on reserves for operational scale. Underwriting emphasizes revenue growth, unit economics, founder alignment and exit-readiness via trade sales or Hong Kong/China IPOs. Typical horizon is 3–7 years with active governance and operational support.

Operates as a Greater China growth private equity allocator that prioritizes technology, consumer and healthcare leaders with clear paths to scalable revenue and cross-border expansion. Capital deployment blends direct equity, structured instruments and co‑investments to balance upside and downside protection, with staged follow‑on reserves for operational scale. Underwriting emphasizes revenue growth, unit economics, founder alignment and exit-readiness via trade sales or Hong Kong/China IPOs. Typical horizon is 3–7 years with active governance and operational support.

Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
35.61%
Gain -0.6%
Monthly
1.52%
Yearly
19.96%
Drawdown
29.3%
$104,580
Equity
Holdings
$104,580
Investment
$93,526
$26.72M
Profit -$508
Realized
$26.71M
Unrealized
$11,054
Dividends
$370,815.73

Goals

Avg. 0% completed goals
Today
Compared To Yesterday
Gain
-0.6%
Profit
-$508
Win %
75%
This Week
Compared To Last Week
Gain
-2%
Profit
-$2,138
Win %
75%
This Month
Compared to last month
Gain
-2%
Profit
-$2,138
Win %
75%
This Year
Compared to last year
Gain
25.12%
Profit
$21,916
Win %
66%
Klothos Neurosciences Inc. logo
KLTO Klothos Neurosciences Inc.
0%
$0
iShares Bitcoin Trust logo
IBIT iShares Bitcoin Trust
-2.76%
-$105
ProShares UltraPro QQQ logo
TQQQ ProShares UltraPro QQQ
-0.76%
-$132
Alphabet Inc logo
GOOG Alphabet Inc
-0.76%
-$271
Loading...

Dividends

Dividend Analysis

Yearly
$
Trades
17
Longs Won
5/17 29%
Profit Factor
3.51
Profitability
Shorts Won
0/0 0%
Standard Deviation
$5.39M
Average Win
$6.44M
Best Trade
(Dec 31) $16.69M
Sharpe Ratio
-8.44
Average Loss
-$765,035.71
Worst Trade
(Sep 29) -$5.93M
Z-Score
1.49 (86.46%)
Commissions
$0
Avg. Trade Length
6m 5d
Expectancy
$1.57M
Loss Size 100% 90% 80% 70% 60% 50% 40% 30% 20% 10%
Probability of Loss <0.01% <0.01% <0.01% <0.01% <0.01% <0.01% <0.01% <0.01% <0.01% <0.01%
Consecutive Losing Trades
Hover over the desired column for a detailed explanation.

Returns

Overall, Monthly
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
Account USV